BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline?
Investors buying this biotech stock now will get its pipeline essentially for free.
Overview
BMO (NYSE: BMO) Capital Markets has been quite bullish about BioNTech SE (NASDAQ: BNTX) this year. However, that's no longer the case.
On Sept. 8, 2026, BioNTech's shares dipped after BMO downgraded the biotech stock from an "outperform" rating to a "market perform" rating. BMO also lowered its 12-month price target for BioNTech from $128 to $105.
Details
There's a simple explanation for BMO's new take on BioNTech. But is Wall Street underestimating the company's cancer pipeline?
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.